Explain
Reading File
analyse_media
analyse_media
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Reading File
I now have all the information needed for a comprehensive explanation. Here is the full breakdown of everything in your notes:
Newer / Novel Antimicrobials
Your notes are organized into 7 categories of newer antimicrobial agents. Here is a full explanation of each:
① Beta-Lactam Antibiotic + Beta-Lactamase Inhibitors
Core concept: Beta-lactamase enzymes are the main resistance mechanism bacteria use to destroy beta-lactam antibiotics. These newer combinations pair a beta-lactam with a novel beta-lactamase inhibitor that protects the antibiotic from destruction.
Cephalosporin + Inhibitor Combinations
| Combination | Generation | Key Inhibitor | Clinical Use |
|---|---|---|---|
| Ceftazidime + Avibactam | 3rd gen | Avibactam (Class A, C, D coverage) | MDR Gram-negatives, ESBL, KPC, P. aeruginosa |
| Ceftolozane + Tazobactam | 3rd gen | Tazobactam | MDR P. aeruginosa, resistant Enterobacterales |
Avibactam is a non-beta-lactam inhibitor that covers Class A (KPC, TEM, SHV, CTX-M), Class C (AmpC), and some Class D (OXA) beta-lactamases - but NOT Class B (metallo-beta-lactamases/MBLs). Both are IV only and reserved for multidrug-resistant infections including complicated UTIs and intra-abdominal infections (with metronidazole). - Lippincott Illustrated Reviews Pharmacology, p. 968
Carbapenem + Inhibitor Combinations
| Combination | Key Inhibitor | Notes |
|---|---|---|
| Meropenem + Vaborbactam | Vaborbactam (boronic acid structure) | Active against KPC-producing CRE; approved for complicated UTIs |
| Imipenem + Relebactam | Relebactam (structurally similar to avibactam) | Also approved for hospital-acquired and ventilator-associated pneumonia |
These combinations target carbapenem-resistant Enterobacteriaceae (CRE) - one of the most serious resistant organisms. - Lippincott Illustrated Reviews Pharmacology, p. 969
4th Generation Cephalosporins
These are listed as a group in your notes:
- Cefepime - widely used 4th gen; broader Gram-negative coverage including P. aeruginosa; better stability against AmpC beta-lactamases than 3rd gen
- Cefpirome - similar spectrum to cefepime
- Cefozopran - used in some countries for MDR Gram-negatives
Why 4th gen? They cross the outer membrane of Gram-negatives more efficiently and are more resistant to beta-lactamase hydrolysis than 3rd gen cephalosporins. - Goodman & Gilman, Antipseudomonal Cephalosporins
Ceftaroline Fosamil (listed as "Cefasoline fosamil" in notes)
A 5th generation cephalosporin (prodrug - converted to ceftaroline in vivo). Unique because it is the only beta-lactam active against MRSA - it binds PBP2a (the altered penicillin-binding protein that gives MRSA resistance). Available only as IV.
② Oxazolidinediones
Your notes list:
- Linezolid
- Tedizolid
These are oxazolidinone antibiotics (note: "oxazolidinediones" in your notes is likely "oxazolidinones"). They work by a unique mechanism - binding the 50S ribosomal subunit and preventing formation of the initiation complex, blocking protein synthesis at a step that other antibiotics do not target. This means no cross-resistance with other protein synthesis inhibitors.
| Drug | Spectrum | Key Use |
|---|---|---|
| Linezolid | Gram-positives (MRSA, VRE, VISA) | MRSA pneumonia, VRE infections |
| Tedizolid | Similar to linezolid, but more potent | Skin/soft tissue infections; fewer drug interactions |
Also listed:
- Glycylcyclines (tetracycline derivative): e.g., Tigecycline - broad-spectrum, active against MDR organisms including MRSA and VRE; used in hospital-acquired infections
- Lipopolysaccharides / Lipopeptides: likely referring to daptomycin class (though this appears in section ⑥ in your notes as lipoglycopeptides)
③ Tetracyclines (Glycylcyclines)
- Eravacycline - novel fluorocycline (next-gen tetracycline)
- Glycylcycline (Tigecycline) - active against MRSA, VRE, Acinetobacter; broad-spectrum; not active against P. aeruginosa
④ Aminoglycosides
Plazomicin
A next-generation aminoglycoside derived from sisomicin. Its key advantage: structural modifications prevent inactivation by most aminoglycoside-modifying enzymes (AMEs) that cause resistance to older aminoglycosides (gentamicin, tobramycin, amikacin). It is FDA-approved for complicated urinary tract infections caused by Enterobacteriaceae including CRE. - Goldman-Cecil Medicine, Aminoglycosides; Harrison's, Mechanisms of Resistance
⑤ Fluoroquinolones
Delafloxacin
A novel fluoroquinolone active against MRSA (unlike older fluoroquinolones). Has both IV and oral formulations. Used for acute bacterial skin infections and community-acquired bacterial pneumonia.
Moxifloxacin
Already clinically established, but grouped here as a "newer" fluoroquinolone. Excellent anaerobic and atypical coverage; used for respiratory infections and TB (as a second-line agent in MDR-TB regimens).
⑥ Lipoglycopeptides - Used in VRE infections
| Drug | Key Points |
|---|---|
| Telavancin | Active against MRSA, VISA, VRSA, some VRE; approved for skin infections and nosocomial pneumonia; causes QT prolongation and nephrotoxicity; interferes with coagulation tests (false elevation of PT) |
| Dalbavancin | Very long half-life (allows once-weekly or even single-dose dosing); approved for skin/soft tissue infections |
These are structurally related to vancomycin but with lipophilic side chains that anchor them to the bacterial membrane. They inhibit cell wall synthesis by binding D-Ala-D-Ala and also disrupt membrane integrity. - Harrison's Principles of Internal Medicine 22E, p. Glycopeptides and Lipoglycopeptides
A third agent in this class, oritavancin, may also have activity against some VRE strains.
⑦ Newer Antitubercular Drugs
These three agents are used for MDR-TB (multidrug-resistant) and XDR-TB (extensively drug-resistant tuberculosis):
| Drug | Class | Mechanism | Use |
|---|---|---|---|
| Bedaquiline | Diarylquinoline | Inhibits mycobacterial ATP synthase (F0 subunit) - unique mechanism, no cross-resistance | Core drug in MDR-TB and XDR-TB regimens; long t½ (~5.5 months); QT prolongation risk; metabolized by CYP3A4 |
| Pretomanid | Bicyclic nitroimidazopyran | (1) Inhibits mycolic acid synthesis under aerobic conditions; (2) generates reactive nitrogen species anaerobically (bactericidal against non-replicating TB) | FDA-approved for XDR-TB as part of BPaL regimen (Bedaquiline + Pretomanid + Linezolid) |
| Delamanid | Bicyclic nitroimidazopyran | Similar to pretomanid; inhibits mycolic acid synthesis | EMA-licensed for MDR-TB |
Bedaquiline kills both actively dividing and non-replicating (dormant/latent) mycobacteria - making it highly effective. - Goodman & Gilman's, Bicyclic Nitroimidazoles; Comprehensive Clinical Nephrology, Newer Drugs
Key "Big Picture" Summary
| Category | Problem Being Solved | Solution |
|---|---|---|
| Beta-lactam + inhibitor combos | Beta-lactamase destroys the antibiotic | Inhibit the enzyme to rescue the beta-lactam |
| 4th gen cephalosporins | AmpC and extended spectrum beta-lactamases | More enzyme-stable ring structure |
| Ceftaroline | MRSA (PBP2a) | Binds even the altered PBP |
| Oxazolidinones | MRSA, VRE | Completely novel ribosome target |
| Plazomicin | AME-mediated aminoglycoside resistance | Structural changes prevent enzyme recognition |
| Lipoglycopeptides | Vancomycin-resistant organisms | Dual mechanism; membrane disruption added |
| Bedaquiline/Pretomanid/Delamanid | MDR/XDR-TB | Novel mechanisms not shared with existing TB drugs |
This is a shared conversation. Sign in to Orris to start your own chat.